444 related articles for article (PubMed ID: 15258910)
1. Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells.
Smith AG; Popov N; Imreh M; Axelson H; Henriksson M
J Cell Biochem; 2004 Aug; 92(6):1282-95. PubMed ID: 15258910
[TBL] [Abstract][Full Text] [Related]
2. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Myc/Max/Mad network members in adipogenesis: inhibition of the proliferative burst and differentiation by ectopically expressed Mad1.
Pulverer B; Sommer A; McArthur GA; Eisenman RN; Lüscher B
J Cell Physiol; 2000 Jun; 183(3):399-410. PubMed ID: 10797315
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the DNA-binding activities of Myc/Max/Mad network complexes during induced differentiation of U-937 monoblasts and F9 teratocarcinoma cells.
Larsson LG; Bahram F; Burkhardt H; Lüscher B
Oncogene; 1997 Aug; 15(6):737-48. PubMed ID: 9264414
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of specific DNA-binding complexes containing members of the Myc/Max/Mad network of transcriptional regulators.
Sommer A; Bousset K; Kremmer E; Austen M; Lüscher B
J Biol Chem; 1998 Mar; 273(12):6632-42. PubMed ID: 9506959
[TBL] [Abstract][Full Text] [Related]
6. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
7. Mad1 expression in the absence of differentiation: effect of cAMP on the B-lymphoid cell line Reh.
Naderi S; Blomhoff HK
J Cell Physiol; 1999 Jan; 178(1):76-84. PubMed ID: 9886493
[TBL] [Abstract][Full Text] [Related]
8. Identification of Max binding protein as a novel binding protein of Nck1 and characterization of its role in inhibiting human liver cancer SK-HEP-1 cells.
Zhou Q; Huang T; Wang YF; Zhang KS; Chen D; Peng BG
Chin Med J (Engl); 2012 Sep; 125(18):3336-9. PubMed ID: 22964333
[TBL] [Abstract][Full Text] [Related]
9. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites.
Hurlin PJ; Quéva C; Eisenman RN
Genes Dev; 1997 Jan; 11(1):44-58. PubMed ID: 9000049
[TBL] [Abstract][Full Text] [Related]
10. Analysis of E-box DNA binding during myeloid differentiation reveals complexes that contain Mad but not Max.
Ryan KM; Birnie GD
Biochem J; 1997 Jul; 325 ( Pt 1)(Pt 1):79-85. PubMed ID: 9224632
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of myc-max-mad gene expression during hepatocyte proliferation in vivo: Differential regulation of mad family and stress-mediated induction of c-myc.
Mauleon I; Lombard MN; Muñoz-Alonso MJ; Cañelles M; Leon J
Mol Carcinog; 2004 Feb; 39(2):85-90. PubMed ID: 14750213
[TBL] [Abstract][Full Text] [Related]
13. Mnt-Max to Myc-Max complex switching regulates cell cycle entry.
Walker W; Zhou ZQ; Ota S; Wynshaw-Boris A; Hurlin PJ
J Cell Biol; 2005 May; 169(3):405-13. PubMed ID: 15866886
[TBL] [Abstract][Full Text] [Related]
14. The Max transcription factor network: involvement of Mad in differentiation and an approach to identification of target genes.
Hurlin PJ; Ayer DE; Grandori C; Eisenman RN
Cold Spring Harb Symp Quant Biol; 1994; 59():109-16. PubMed ID: 7587059
[TBL] [Abstract][Full Text] [Related]
15. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
[TBL] [Abstract][Full Text] [Related]
16. Lack of correlation between N-myc and MAX expression in neuroblastoma tumors and in cell lines: implication for N-myc-MAX complex formation.
Raschella G; Romeo A; Negroni A; Pucci S; Dominici C; Castello MA; Bevilacqua P; Felsani A; Calabretta B
Cancer Res; 1994 Apr; 54(8):2251-5. PubMed ID: 8174135
[TBL] [Abstract][Full Text] [Related]
17. Mnt: a novel Max-interacting protein and Myc antagonist.
Hurlin PJ; Qúeva C; Eisenman RN
Curr Top Microbiol Immunol; 1997; 224():115-21. PubMed ID: 9308234
[TBL] [Abstract][Full Text] [Related]
18. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH
Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458
[TBL] [Abstract][Full Text] [Related]
19. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
Gupta K; Anand G; Yin X; Grove L; Prochownik EV
Oncogene; 1998 Mar; 16(9):1149-59. PubMed ID: 9528857
[TBL] [Abstract][Full Text] [Related]
20. Targeting of the MYCN protein with small molecule c-MYC inhibitors.
Müller I; Larsson K; Frenzel A; Oliynyk G; Zirath H; Prochownik EV; Westwood NJ; Henriksson MA
PLoS One; 2014; 9(5):e97285. PubMed ID: 24859015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
